Core Viewpoint - The acquisition of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. by BGI Genomics is a strategic move to enhance its capabilities in the fields of spatial omics and nanopore sequencing, positioning the company as a leader in the global life sciences sector with a comprehensive product matrix covering "full-length sequencing + spatial omics" [1][2][3]. Group 1: Acquisition Details - BGI Genomics plans to acquire 100% equity of both companies for a total consideration of approximately 366 million yuan [1]. - The acquisition will allow BGI Genomics to integrate cutting-edge technologies into its operations, enhancing its product offerings and market position [2][3]. Group 2: Technological Integration - The acquisition will create a seamless technology chain combining short-read (DNBSEQ), long-read (CycloneSEQ), and spatial omics (Stereo-seq) technologies, making BGI Genomics the only company globally to cover these three advanced technologies [2][3]. - Stereo-seq technology is recognized for its international leadership in resolution and field of view, with applications in neuroscience, regenerative medicine, and tumor microenvironment analysis [2][3]. - CycloneSEQ technology offers unique advantages such as long-read, real-time sequencing, and portability, effectively addressing challenges in large genome assembly and clinical testing [2][3]. Group 3: Strategic Advantages - The acquisition strengthens BGI Genomics' first-mover advantage in the AI medical field, enhancing its "AI + gene sequencing" strategy and supporting the development of intelligent laboratory automation [4]. - The integration of these technologies will enable BGI Genomics to provide comprehensive services from library construction to sequencing and data analysis, significantly improving customer service capabilities and retention [3]. Group 4: Financial Considerations - The acquisition is strategically timed to capitalize on the valuation window during the target companies' incubation phase, allowing BGI Genomics to acquire assets at a more realistic value [5]. - The estimated equity value of Huada Sanjian is 158 million yuan, while Huada Xufeng is valued at 207.7 million yuan, both assessed using the income method [5]. - Performance guarantees from the sellers include commitments for cumulative net profits of at least 50.1 million yuan for Huada Sanjian and 82.8 million yuan for Huada Xufeng over specified periods, with cash compensation provisions in case of unmet targets [6]. Group 5: Market Impact - The acquisition is expected to significantly enhance BGI Genomics' revenue scale and profitability, leveraging its global sales network to promote the new technologies [6]. - The integration of new revenue streams from spatial omics and nanopore sequencing will contribute to the company's long-term growth and industry influence [6]. - The transaction aligns with the broader trend of deep mergers and acquisitions in the industry, reflecting a focus on strategic integration and value creation [6].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Viewpoints - The Chinese biopharmaceutical sector is expected to enter a new era of innovative drug exports in 2026, with significant opportunities arising from strategic acquisitions and internal research and development [3][8] - The report emphasizes the importance of selecting strong fundamental innovative drug stocks that have undergone sufficient adjustments, as well as actively monitoring new medical technologies and companies poised for recovery in 2026 [4][41] Summary by Sections Industry Performance - From January 26 to January 30, the pharmaceutical index fell by 3.31%, underperforming the CSI 300 index by 3.39%. Notably, the market has seen a significant adjustment in the innovative drug sector since August 2025, with the lowest holdings in active funds since 2021 [5][21] - The report highlights that 58 stocks rose while 407 stocks fell during the week, with notable gainers including Cap Bio (+26.49%) and Hualan Biological (+12.80%) [5][22] Company Insights - China Biopharmaceutical is enhancing its core competitiveness through strategic acquisitions and self-research, which is expected to lead to more opportunities for international expansion. The acquisition of Hegia in January 2026 and Lixin Pharmaceutical in July 2025 are key moves to strengthen its pipeline in chronic diseases and oncology [8][13] - The report identifies Hegia's siRNA delivery technology as a significant advancement, allowing for long-lasting treatment options in chronic diseases, while Lixin's unique LM-TME platform is expected to enhance the company's capabilities in oncology [9][11][14] Investment Recommendations - The report suggests focusing on innovative drug companies such as Heng Rui Medicine, Xin Li Tai, and China Biopharmaceutical, as well as companies involved in new medical technologies like AI healthcare and brain-computer interfaces [41][43] - It also highlights the potential for recovery in the medical device and pharmaceutical manufacturing sectors in 2026, recommending stocks that are currently undervalued [41][42] Market Trends - The report notes that the Chinese pharmaceutical industry has completed a transition from generic to innovative drugs, with companies like Heng Rui Medicine and China Biopharmaceutical leading the way in innovation [41][42] - The aging population and increasing healthcare demands are expected to drive growth in the sector, supported by a stable increase in medical insurance revenues and the development of a multi-tiered payment system [41][42]

Core Viewpoint - BGI Genomics (688114.SH) announced plans to acquire 100% equity of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd. for a total of 366 million yuan, enhancing its core technology layout and solidifying its position as a global leader in gene sequencing [1] Group 1: Acquisition Details - The acquisition aims to integrate two core assets: spatiotemporal omics and nanopore sequencing, marking a significant step in BGI Genomics' strategic development [1] - This move establishes a unique technological barrier in the upstream life sciences sector, combining short-read, long-read, and spatial omics technologies into a comprehensive product matrix [1][2] Group 2: Technological Advancements - The long-read technology (CycloneSEQ) has achieved industry-leading levels in terms of single-chip throughput and methylation direct measurement, comparable to international leader ONT [2] - The spatiotemporal omics technology (Stereo-seq) significantly outperforms similar products from 10X Genomics in terms of capture area, resolution, and multi-level analysis capabilities [2] Group 3: Financial Aspects - The acquisition is characterized as a "low-cost, high-value" strategic move, with pricing accurately reflecting the actual business value of the target companies [2] - Performance commitments from the target companies, along with cash compensation and impairment compensation mechanisms, are in place to mitigate risks and protect investor interests [2] Group 4: Strategic Positioning - This acquisition strengthens BGI Genomics' first-mover advantage in the AI healthcare sector, where it has already established a leading position with its "AI + gene sequencing" strategy [3] - The integration of Stereo-seq technology provides precise navigation capabilities essential for breakthroughs in implantable brain-computer interface technology [3] - Market analysts view this acquisition as a cost-effective expansion strategy that enhances the company's long-term profitability and industry influence through a unique technological chain [3]

医药生物 行 业 研 究 2026 年 02 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-02 2025-06 2025-10 医药生物 沪深300 相关研究报告 《原料药行业价格更新—行业周报》 -2026.1.25 《业绩为王，继续重点推荐创新药产 业链板块性机会 — 行 业 周 报 》 -2026.1.18 《减重新靶点初显锋芒，小核酸疗法 前景可期—行业周报》-2026.1.11 供需双改善，国内临床 CRO 行业进入发展新阶段 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | | --- | --- | | | liuyi1@kysec.cn | | yuruyi@kysec.cn | | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | liuyi1@kysec.cn 证书编号：S0790124070022 中国临床 CRO 行业进入"复苏+稳健增长"新阶段，供需结构持续改善 中国创新药产业已完成从十年前的"离岸外包服务模式"到如今"全球创新资产的 贡献者"的跃迁。临 ...

Group 1 - February macro outlook indicates a favorable macro environment for equity markets, with expectations of strong economic and credit data at the beginning of the year [7][9] - The strategy outlook suggests a transition in market styles, with a focus on growth "rest" and a continued bullish stance while adjusting portfolio structures [9][10] - The quantitative strategy emphasizes investing in small-cap stocks and taking long positions before the Spring Festival [10] Group 2 - The February gold stock selection includes companies from various sectors: - Electronics: Shiyun Circuit, Shengkong Co. - Consumer Electronics: Baiwei Storage - Computing: Yunsai Zhiliang - Communication: Kexin Innovation Source - Non-ferrous Metals: Shengtun Mining, Luoyang Molybdenum - Machinery: Zhonglian Heavy Industry - Coal: Huaibei Mining - Non-bank Financials: Dongfang Securities [12][14] - The rationale for selected stocks includes: - Shiyun Circuit is expected to benefit from emerging fields such as commercial aerospace and intelligent driving, potentially leading to significant growth [13] - Shengkong Co. is positioned to gain from the semiconductor cycle, with demand driven by AI and storage needs [17] - Baiwei Storage is set to capitalize on the AI infrastructure boom, with a focus on domestic market share growth [20] - Yunsai Zhiliang is anticipated to see increased demand for cloud services and IDC, driven by AI advancements [22] - Kexin Innovation Source is expected to achieve breakthroughs in the AI liquid cooling market, enhancing revenue and profitability [26] - Shengtun Mining is projected to improve profitability through copper price increases and strategic acquisitions [31] - Luoyang Molybdenum is expected to benefit from increased copper and cobalt production, alongside new gold mining projects [35] - Zhonglian Heavy Industry is positioned for growth through diversification in machinery sectors and global expansion [40] - Huaibei Mining is highlighted for its high elasticity in coking coal, with price improvements expected in 2026 [46] - Dongfang Securities is set to benefit from regulatory support and potential mergers, enhancing its market position [49]

证券研究报告 科技有哪些积极进展和后续看点？ ——每周主题、产业趋势交易复盘和展望 证券分析师：陈刚 执业证书编号：S0600523040001 邮箱：cheng@dwzq.com.cn 研究助理：孔思迈 执业证书编号：S0600124070019 邮箱：kongsm@dwzq.com.cn 2026年2月1日 注：本报告所涉及个股/公司仅代表与产业或交易热点有关联，所引述资讯/数据/观点仅以展示为目的，不构成投资建议，个股层面请参照东吴证券研究所各行业组所推荐标的。 目录 1、本周市场回顾 2、产业趋势交易回顾与展望 3、风险提示 2 注：本报告所涉及个股/公司仅代表与产业或交易热点有关联，所引述资讯/数据/观点仅以展示为目的，不构成投资建议，个股层面请参照东吴证券研究所各行业组所推荐标的。 1. 本周市场回顾 注：本周交易日为1月26日-30日 （如无特殊说明）后文同 3 注：本报告所涉及个股/公司仅代表与产业或交易热点有关联，所引述资讯/数据/观点仅以展示为目的，不构成投资建议，个股层面请参照东吴证券研究所各行业组所推荐标的。 一：大盘表现 ✓ 上证指数走势 4 注：本报告所涉及个股/公司仅代表与产业或 ...

Core Viewpoint - The article emphasizes the commitment of Haikou to accelerate the construction of the Hainan Free Trade Port, aiming to position it as a significant gateway for China's new era of opening up to the world [1][2]. Group 1: Economic Development - Haikou will implement the spirit of the provincial two sessions, promoting a pioneering and hardworking attitude to achieve economic and social development goals [2]. - The city aims to expand its openness by fully implementing free trade port policies and transforming policy dividends into development momentum [2]. - There is a focus on deepening cooperation with countries and regions involved in the Belt and Road Initiative and exploring new collaborative scenarios with the Guangdong-Hong Kong-Macao Greater Bay Area [2]. Group 2: Industry Growth - The development strategy includes fostering four types of industries: strategic support, free trade characteristics, future emerging, and empowerment guarantee industries [2]. - Key sectors such as biomanufacturing, hydrogen energy, and brain-computer interface industrialization will be supported, along with optimizing and upgrading leading industries [2]. - The city will promote high-quality development in key areas like airport economy, port industries, and headquarters economy, while exploring Transit-Oriented Development (TOD) models [2]. Group 3: Reform and Innovation - There will be a focus on deepening reform and innovation in key areas, aiming to produce more globally influential and recognizable institutional innovations [2]. - The city plans to enhance standardized and non-standardized services, extending the approach of "solving one issue" to "handling a category of issues" to create a first-class business environment [2]. Group 4: Social Welfare - Haikou will invest more policies, funds, and resources into public welfare, emphasizing inclusive, foundational, and safety-net social construction [3]. - The city aims to advance urban health checks and urban renewal in a coordinated manner [3].

行 机械设备 2026 年 01 月 31 日 业 研 究 机械设备 超声脑机接口启新篇，中国方案破解脑病治疗困局 投资要点： "十五五"重点赛道，脑机接口市场规模有望快速增长 根据 precedence research，2024 年全球脑机接口市场规模约为 26.2 亿美元，预计 2025 年将达到 29.4 亿美元，到 2034 年有望增长至 124 亿美元，十年间复合年增长率为 17.35%；据工信微报，2024 年中国脑 机接口市场规模为 32.0 亿元，预计到 2028 年将达 61.4 亿元。《中共 中央关于制定国民经济和社会发展第十五个五年规划的建议》提出前 瞻布局未来产业，推动脑机接口等成为新的经济增长点。这些产业蓄 势发力，未来 10 年将再造一个中国高技术产业。 建议关注 岩山科技、汉威科技、三博脑科、创新医疗、东方中科、翔宇医 疗、熵基科技、诚益通、伟思医疗、麦澜德、爱朋医疗、倍益康等。 风险提示 证 市场竞争加剧、政策支持力度不及预期、技术研发及新产品开发 不利、脑机产品造成病患受伤等风险 技术突破创新，超声精准打开血脑屏障 行 业 定 期 报 告 近日，复旦大学联合华山医院在国家重 ...

行 机械设备 2026 年 01 月 31 日 业 研 究 机械设备 超声脑机接口启新篇，中国方案破解脑病治疗困局 投资要点： 技术突破创新，超声精准打开血脑屏障 行 业 定 期 报 告 近日，复旦大学联合华山医院在国家重点研发计划项目启动会上， 发布国内首例采用自主研制超声诊疗一体化装置"UltraBrainPad"的临 床试验成果。该半侵入式技术为全球第三种方案，通过手持式探头结 合 AI 图像识别，3 分钟即可打开胶质母细胞瘤患者血脑屏障，药物浓 度平均提升 8 倍，6 小时后屏障自动关闭，操作便捷、成本可控且安全 性优于国际水平，成功破解传统技术感染风险高、精度不足等难题。 赛道拓展赋能，惠及多种脑病治疗场景 作为国家重点研发计划项目，该技术已启动复发胶质母细胞瘤临 床研究，未来将打造超声脑机接口新赛道。除脑肿瘤药物治疗外，其 科研成果还将向神经调控、脑机融合方向转化，有望为阿尔兹海默病、 头痛、失眠等多种脑病提供全新治疗路径，凭借基层可及的优势，让 更多患者受益于这一"中国方案"。 岩山科技、汉威科技、三博脑科、创新医疗、东方中科、翔宇医 疗、熵基科技、诚益通、伟思医疗、麦澜德、爱朋医疗、倍益康等。 ...

丨证券研究报告丨 行业研究丨点评报告丨软件与服务 [Table_Title] 2 项医疗器械行业标准制修订项目立项，脑机接 口再迎政策利好 报告要点 [Table_Summary] 1 月 28 日，据国家药监局官网消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质 量发展，经研究，国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功 能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性验证方法》等 2 项医疗器械行业标 准制修订项目立项。政策层面的持续完善有望为脑机接口的发展提供了关键推力，加速脑机接 口产业商业化落地。建议关注三条主线：1、侵入式脑机接口海外先进产业链的国内映射标的； 2、非侵入式脑机接口在消费场景的产品落地相关标的；3、脑机接口下游应用端相关标的。 分析师及联系人 [Table_Author] 宗建树 陈耀文 SAC：S0490520030004 SAC：S0490525070002 SFC：BUX668 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 软件与服务 cjzqdt11111 [Table_Title 2 项 ...